FALLS CHURCH, Va., Sept. 4 /PRNewswire/ -- FDAnews today announced the
launch of Drug Industry Daily, an electronic daily briefing that provides
coverage of what's happening on Capitol Hill, in the courts and at the FDA,
the FTC, HHS, NIH and other key agencies and decision making bodies that
affect the pharmaceutical industry.
Each issue gives you hard reporting on top issues such as patent
exclusivity, DTC advertising, medication errors, program funding, FDA
appropriations, bioterrorism, warnings, recalls, approvals and more.
"It's never been harder -- or more important -- to keep track of all
that's going on and who the players are," said Cynthia A. Carter, publisher of
FDAnews. "The drug industry is under fire from many directions, from pricing
to safety. Multiple bills are in Congress, countless lawsuits are in the
courts and FDA enforcement actions are aimed straight at drug companies'
At the same time, developments in drug discovery offer extraordinary
opportunities. With so much to keep track of and many contingencies trying to
shape the outcome, industry insiders need a reliable source of current
developments. Drug Industry Daily delivers the unbiased news every day, so
readers get the latest word as the story unfolds, from beginning to end.
Lobbyists, government policy makers, industry executives, investment
specialists and consultants whose very job is to shape the future of the drug
industry use Drug Industry Daily. Anyone who needs to know about developments
as they happen will benefit from subscribing.
For a limited time, Drug Industry Daily is being offered at an
introductory rate of $1,495 per year (a $400 savings off the regular price of
$1,895). To become a charter subscriber, phone customer service at
+1-703-538-7600 or go to http://www.fdanews.com/pub/did/.
Drug Industry Daily is published by FDAnews, publishers of Washington Drug
Letter, The Food & Drug Letter, Part 11 Compliance Report, Generic Line,
Devices & Diagnostics Letter, Regulatory Watchdog Service, Genomics Newswire
and many other information services to help pharmaceutical, biotech and
medical device executives meet regulatory and business challenges.
MAKE YOUR OPINION COUNT - Click Here